Brief: Hofseth Biocare: Aecorbio Secures Further $1.5 Mln At $30 Mln Valuation
17/09/2025 08:00
Sept 17 (Reuters) - Hofseth Biocare ASA HBC.OL: HOFSETH BIOCARE ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUATION FOR ONGOING FT-002A PEPTIDE DEVELOPMENT IN PROSTATE CANCER Source text: ID:nGNE1XNnqt Further company coverage: HBC.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hofseth Biocare ASA
See all newsBrief: HBC Publishes Clinical Trial, Calls It Paradigm-Changing
Brief: Hofseth Biocare Says Demand Outlook For 2026 Is Improving Rapidly
Norway's Hofseth Biocare Q4 revenue rises on Human Nutrition demand
Brief: Hofseth BioCare To Cancel Subsequent Offering
Brief: Hofseth Biocare Announces Results Of Subsequent Offering